<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335164</url>
  </required_header>
  <id_info>
    <org_study_id>FLU003</org_study_id>
    <nct_id>NCT02335164</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults</brief_title>
  <acronym>FLU003</acronym>
  <official_title>A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxine Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Flinders University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian Respiratory and Sleep Medicine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vaxine Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recombinant hemagglutinin has been shown to induce protective neutralising antibodies against
      avian influenza virus but is relatively non-immunogenic. An ideal pandemic avian influenza
      influenza vaccine would combine hemagglutinin antigen with an appropriate adjuvant to
      increase its immunogenicity. This Phase 1 study will collect preliminary human safety and
      efficacy data on combined formulations of recombinant hemagglutinin with Advax adjuvant
      formulations administered by intramuscular injection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to test new vaccine formulations against pandemic avian influenza (&quot;bird
      flu&quot;). Bird flu is a potentially deadly disease that is caused by influenza virus from birds.
      It is not the same as the common seasonal flu for which there is a seasonal vaccine released
      around March each year. To date, bird flu due to the H5N1 strain of influenza virus has
      infected over 500 people mainly in Asia resulting in death in more than half the cases. More
      recently there has been an outbreak of another bird flu virus in China known as H9N7 that is
      also highly lethal when it infects humans. Vaccination is the single most effective measure
      to prevent infection from bird flu viruses such as H5N1 or H9N7 should such a pandemic occur.
      In the event of a major bird flu pandemic outbreak, vaccine supplies are likely to be very
      limited, as there is not currently sufficient manufacturing capacity to provide enough
      vaccine quickly for the whole population. Research is needed on how to make the pandemic flu
      vaccine more effective but also how to stretch vaccine supplies using a strategy called
      'antigen-sparing'. This can potentially be achieved by using an important ingredient called
      an 'adjuvant'. Adjuvants act by stimulating the immune system to make vaccines more
      effective. This study will test Advax adjuvants which are based on delta inulin in
      combination with recombinant hemagglutinin from the H5N1 influenza virus serotype.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>The frequency of adverse events will be compared between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination inhibition assay</measure>
    <time_frame>1 month post each immunization and 11 months post final immunization</time_frame>
    <description>Seroconversion, seroprotection and GMT fold increase will be compared between groups at each time point using hemagglutination inhibition titers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasmablast response</measure>
    <time_frame>7 and 28 days post each immunization</time_frame>
    <description>The size of the plasmablast response will be compared between groups as an experimental endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>T-cell response</measure>
    <time_frame>7 and 28 days post each immunization</time_frame>
    <description>The size of the memory T cell response will be compared between groups as an experimental endpoint</description>
  </other_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>HA 45ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 45ug+Advax1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 45ug+Advax2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 15ug+Advax1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 15ug+Advax2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 5ug+Advax1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 5ug+Advax2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 2.5ug+Advax2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 15ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant influenza hemagglutinin</intervention_name>
    <description>recombinant influenza hemagglutinin</description>
    <arm_group_label>HA 45ug</arm_group_label>
    <arm_group_label>HA 45ug+Advax1</arm_group_label>
    <arm_group_label>HA 45ug+Advax2</arm_group_label>
    <arm_group_label>HA 15ug+Advax1</arm_group_label>
    <arm_group_label>HA 15ug+Advax2</arm_group_label>
    <arm_group_label>HA 5ug+Advax1</arm_group_label>
    <arm_group_label>HA 5ug+Advax2</arm_group_label>
    <arm_group_label>HA 2.5ug+Advax2</arm_group_label>
    <arm_group_label>HA 15ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Advax1</intervention_name>
    <description>Delta inulin adjuvant formulation 1</description>
    <arm_group_label>HA 45ug+Advax1</arm_group_label>
    <arm_group_label>HA 15ug+Advax1</arm_group_label>
    <arm_group_label>HA 5ug+Advax1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Advax2</intervention_name>
    <description>Delta inulin adjuvant formulation 2</description>
    <arm_group_label>HA 45ug+Advax2</arm_group_label>
    <arm_group_label>HA 15ug+Advax2</arm_group_label>
    <arm_group_label>HA 5ug+Advax2</arm_group_label>
    <arm_group_label>HA 2.5ug+Advax2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory males or females aged 18 years and over

          -  Able to provide written informed consent

          -  Willing and able to comply with the protocol for the duration of the study.

          -  Not planning to have seasonal influenza vaccine within 2 months from the time of the
             first trial immunization

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Women of childbearing potential unless using a reliable and appropriate contraceptive
             method.

          -  Receipt of another investigational agent within 28 days preceding initiation of
             treatment.

          -  Any other serious medical, social or mental condition which, in the opinion of the
             investigator, would be detrimental to the subjects or the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitar Sajkov, FRACP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flinders University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flinders University</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2015</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

